Most patients with appendix cancer may avoid chemotherapy after surgery, study suggests
Most patients with localized appendix cancer may be able to safely avoid chemotherapy after surgery, according to a new study from researchers at The University of Texas MD Anderson Cancer Center.
A recent study from The University of Texas MD Anderson Cancer Center suggests that most patients with localized appendix cancer may be able to avoid chemotherapy after surgery. The research, published in JAMA Surgery, found that fewer than 10% of patients experienced cancer recurrence after surgery, and chemotherapy did not improve survival or reduce the risk of relapse, even among higher-risk patients.
The study, led by Dr. John Paul Shen and Dr. Sacha El Khoury, is the largest to date of localized appendix cancer. Dr. Shen stated that appendix cancer has a distinct biology and that the risk of relapse is low for most patients with localized disease. Understanding each tumor's unique characteristics can help identify those who may benefit from closer monitoring without unnecessary treatment.
Researchers identified specific genetic changes, such as TP53 and GNAS mutations, which were associated with a higher risk of cancer returning. This analysis highlights the need to consider tumor histology and molecular features to better predict recurrence risk and tailor treatment accordingly. While the study has limitations, including its single-center treatment location, it offers valuable insights into the unique nature of appendix cancer and the potential to refine treatment strategies based on individual tumor characteristics.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
